Form 8-K - Current report:
SEC Accession No. 0001558370-25-008430
Filing Date
2025-06-05
Accepted
2025-06-05 16:01:51
Documents
16
Period of Report
2025-06-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20250605x8k.htm   iXBRL 8-K 79671
2 EX-3.1 acrs-20250605xex3d1.htm EX-3.1 10502
3 EX-10.1 acrs-20250605xex10d1.htm EX-10.1 166377
4 EX-10.2 acrs-20250605xex10d2.htm EX-10.2 85089
5 EX-10.3 acrs-20250605xex10d3.htm EX-10.3 70311
  Complete submission text file 0001558370-25-008430.txt   599010

Data Files

Seq Description Document Type Size
6 EX-101.SCH acrs-20250605.xsd EX-101.SCH 3422
7 EX-101.LAB acrs-20250605_lab.xml EX-101.LAB 16568
8 EX-101.PRE acrs-20250605_pre.xml EX-101.PRE 10687
18 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20250605x8k_htm.xml XML 4978
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 251027019
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)